Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Baden-Baden – page 49

1 153 clinical trials in Baden-Baden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Baden-Baden at a glance
1 153
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 153 trials in Baden-Baden

Open in trial search

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Hospices Civils De Lyon

Acute kidney injury

Not yet recruiting

Study on Nicotinamide for Patients with Acute Kidney Injury

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Assistance Publique Hopitaux De Marseille

Psychotic disorder+1

Not yet recruiting

Study on Reducing Antipsychotic Dose vs. Maintenance Treatment for Patients with Schizophrenia Using Haloperidol Decanoate, Risperidone, and Amisulpride

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Amisulpride
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Diffuse large B-cell lymphoma+2

Not yet recruiting

Study of Loncastuximab Tesirine and Epcoritamab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, or Follicular Lymphoma Grade 3B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Study on the Effects of INT230-6, Vinblastine Sulfate, and Cisplatin in Patients with Early Triple-Negative Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Swiss Group for Clinical Cancer Research

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Renal cancer

Not yet recruiting

Study of Nivolumab and Ipilimumab or Drug Combination for Patients with Metastatic Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:ARTIC

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Renal transplant

Not yet recruiting

Study on Eplerenone for Heart Health in Kidney Transplant Patients Using Cyclosporine or Tacrolimus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eplerenone
  • Sponsor:CHRU De Nancy

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Baden-Baden

What the registry says about research in the country

01 Eye Diseases and Ocular Physiology

Clinical research in Baden-Baden includes studies focused on eye diseases and ocular physiological phenomena, with attention on atrophic age-related macular degeneration. These trials are exploring ways to slow disease progression and better understand vision-related decline.

  • Testing a new approach for geographic atrophy linked to AMD
  • Evaluating treatment effectiveness in progressive retinal disease

The goal is to improve care for patients facing gradual loss of vision through more effective targeted therapies.

02 Neoplasms in Breast Cancer Research

A major part of the clinical trial activity in the city centers on breast cancer, including HER2+, HR+/HER2-, and triple-negative early breast cancer. These studies are examining new treatment combinations to strengthen disease control and improve long-term outcomes.

  • Assessing new therapy combinations for HER2+ early breast cancer
  • Comparing treatment strategies in HR+/HER2- early breast cancer
  • Studying options for triple-negative early breast cancer

Research in this area is aimed at improving response rates and reducing the chance of recurrence after initial treatment.

03 Hemic and Lymphatic Diseases

Trials in hematologic malignancies are investigating new strategies for patients with high-risk chronic lymphocytic leukemia. The focus is on whether newer drug combinations can offer stronger disease control than current standard approaches.

  • Evaluating combination treatment for high-risk CLL
  • Studying outcomes in patients with adverse genetic risk factors

These studies are designed to improve progression control and support more personalized treatment choices.

04 Ovarian and Gynecologic Cancer

Another active research area involves advanced ovarian cancer and related gynecologic cancers, including fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The trials are examining treatment strategies for patients with no visible residual tumor after surgery.

  • Studying maintenance approaches in HRD-positive high-grade ovarian cancer
  • Evaluating recurrence prevention after primary tumor debulking

These efforts aim to extend recurrence-free survival and refine post-surgical treatment planning.

05 Personalized Oncology in Early Breast Cancer

Several studies are exploring personalized cancer therapy for early-stage breast cancer, using treatment selection to match individual risk profiles. This includes approaches that combine targeted medicine, endocrine therapy, and other systemic treatments.

  • Testing personalized treatment for intermediate- to high-risk HR+/HER2- breast cancer
  • Comparing targeted therapy with standard adjuvant care
  • Improving invasive disease-free survival in early cancer care

In Baden-Baden, this line of research reflects a broader move toward more tailored and effective cancer treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.